Prostate cancer (PCa) is globally the second most diagnosed cancer type and the most
common cause of cancer-related deaths in men. Family history of PCa, hereditary breast …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

Prostate cancer (PrCa) ranks among the top five cancers for both incidence and mortality
worldwide. A significant proportion of PrCa susceptibility has been attributed to inherited …

Purpose: Genomic alterations in DNA damage repair (DDR) genes other than BRCA may
confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate …

Talazoparib, a PARP inhibitor, is active in germline BRCA1 and BRCA2 (g BRCA1/2)-mutant
advanced breast cancer, but its activity beyond g BRCA1/2 is poorly understood. We …

Background Germline variant evaluation in precision oncology opens new paths toward the
identification of patients with genetic tumor risk syndromes and the exploration of therapeutic …

Different mutational processes leave characteristic patterns of somatic mutations in the
genome that can be identified as mutational signatures. Determining the contributions of …

Performing germline and somatic sequencing in locally advanced and metastatic pancreatic
cancer can identify potentially targetable genomic aberrations that impact current standard …

Abstract Background An important fraction (>/~ 10%) of men with high‐risk, localized
prostate cancer and metastatic prostate cancer carry germline (heritable) pathogenic and …

Despite remarkable progress in the last decade, metastatic prostate cancer (mPCa) remains
incurable. The approval of PARP inhibitors (PARPis) represents a milestone in this field …